Gilead Sciences has secured approval from the US Food and Drug Administration (FDA) for supplemental indications of Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi (sofosbuvir 400 mg) tablets for chronic hepatitis C virus (HCV) infection treatment in adolescents without cirrhosis or with compensated cirrhosis, 12 years of age and older, or weighing at least 35kg.
News from Twitter
Looking forward to meeting you all at #BIO2017 San Diego, June 19-22, 2017. Let's schedule: 1 (800) 445-1839 // +41 22 518 2100
Scopis launches mixed reality spinal surgery navigator with Microsoft’s HoloLens captis.com/scopis-la…
One Drop, MannKind ink partnership for connected, inhaled diabetes tech captis.com/?p=33587
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News